This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Merck's (MRK) Meets Goal in Muscle-Invasive Bladder Cancer Study
by Zacks Equity Research
Data from a late-stage study shows that Merck's (MRK) Keytruda lowered the risk of disease recurrence or death when used after surgery in certain patients with urothelial carcinoma.
(MRK) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
In the most recent trading session, Merck (MRK) closed at $103.60, indicating a +1.4% shift from the previous trading day.
FDA Accepts Merck's (MRK) Filing for Sotatercept in PAH Disease
by Zacks Equity Research
The FDA grants priority review to Merck's (MRK) FDA filing for sotatercept to treat adults with pulmonary arterial hypertension. A final decision is expected before March 2023-end.
J&J's (JNJ) Rybrevant Combo Meets Primary Goal in NSCLC Study
by Zacks Equity Research
J&J (JNJ) meets the primary goal in the late-stage study of the combination therapy of Rybrevant and lazertinib against Tagrisso for EGFR-mutated first-line NSCLC.
AstraZeneca (AZN) Key Drugs to Aid Growth, Pipeline Strong
by Zacks Equity Research
AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Fasenra and Farxiga should keep driving revenues. Its pipeline is strong, with several phase III data readouts lined up.
Brokers Suggest Investing in Merck (MRK): Read This Before Placing a Bet
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Merck (MRK). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
The Zacks Analyst Blog Highlights AbbVie, Lilly, Sanofi, Merck and J&J
by Zacks Equity Research
AbbVie, Lilly, Sanofi, Merck and J&J are included in this Analyst Blog.
Merck (MRK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $102.95, moving -1.29% from the previous trading session.
Pharma Stock Roundup: FDA and EMA Regulatory Updates for ABBV, LLY, SNY & MRK's Drugs
by Kinjel Shah
The European Commission approves AbbVie's (ABBV) Tepkinly (epcoritamab) for DLBCL. FDA approves Lilly's (LLY) Jardiance for chronic kidney disease.
Bionomics (BNOX) Meets Goals in PTSD Study, Stock Rallies 244%
by Zacks Equity Research
Bionomics (BNOX) announces positive top-line results from its mid-stage study of BNC210 for the treatment of Post-Traumatic Stress Disorder. The stock of the company rallies 244%.
Ligand (LGND) Acquires Certain Assets of Novan for $12.2M
by Zacks Equity Research
Following the acquisition, Ligand (LGND) has full ownership rights to berdazimer gel, all assets related to NITRICIL drug delivery technology platform and rights to the Sitavig program.
The Zacks Analyst Blog Highlights Alphabet, Exxon Mobil, Merck, Abbott Laboratories and NextEra Energy
by Zacks Equity Research
Alphabet, Exxon Mobil, Merck, Abbott Laboratories and NextEra Energy are part of the Zacks top Analyst Blog.
Merck (MRK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $103.94, moving -1.38% from the previous trading session.
Top Stock Reports for Alphabet, Exxon Mobil & Merck
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Exxon Mobil Corp. (XOM) and Merck & Co., Inc. (MRK).
Merck (MRK), Eisai Combo Therapy Fail Two Lung Cancer Studies
by Zacks Equity Research
Data from both late-stage studies evaluating Merck's (MRK) Keytruda and Eisai's Lenvima combination in certain types of metastatic non-small cell lung cancer, fail to achieve their primary endpoints.
Seagen's (SGEN) Combo Drug Meets Goals in Bladder Cancer Study
by Zacks Equity Research
Seagen (SGEN) announces positive top-line results from its late-stage study of the Padcev/Keytruda combo in the treatment of adult patients with metastatic bladder cancer. The stock of the company rises 3.5%.
The Zacks Analyst Blog Highlights Pfizer, Merck and AstraZeneca
by Zacks Equity Research
Pfizer, Merck and AstraZeneca are part of the Zacks top Analyst Blog.
Bristol Myers' (BMY) Opdivo Positive in Late-Stage NSCLC Study
by Zacks Equity Research
Bristol Myers' (BMY) perioperative regimen of neoadjuvant Opdivo with chemotherapy, followed by surgery and adjuvant Opdivo, improves event-free survival in NSCLC.
Pharma Stock Roundup: EU Nod to PFE's Litfulo, FDA Priority Tag to MRK Applications
by Kinjel Shah
The European Commission approves Pfizer's (PFE) Litfulo for severe alopecia areata. FDA gives priority tag to Merck's (MRK) supplemental applications for Welireg and Keytruda.
Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SCHD
Merck (MRK) Stock Moves -0.54%: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $106.73, marking a -0.54% move from the previous day.
Merck (MRK) Keytruda Cervical Cancer sBLA Gets FDA Priority Tag
by Zacks Equity Research
The FDA grants priority review to Merck's (MRK) sBLA seeking expanded use of Keytruda for an earlier stage of cervical cancer disease.
Merck (MRK) Stock Moves -0.05%: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $107.31, marking a -0.05% move from the previous day.
FDA Accepts Merck (MRK) sNDA for Welireg in Renal Cell Carcinoma
by Zacks Equity Research
The FDA filing is supported by data from a late-stage study that shows that Merck's (MRK) Welireg achieved statistically significant and clinically meaningful improvement in progression-free survival.
Ligand (LGND) to Spin Out Pelican Subsidiary, Updates '23 View
by Zacks Equity Research
Ligand (LGND) intends to spin out and merge its subsidiary Pelican with Primordial Genetics to form a new standalone company. Post-merger, it will own a 49.9% stake in this new company.